Choreito,一种日本康波药,用于治疗日本女性患者,以快速缓解与急性膀胱炎相关的炎症症状。我们评估了Choreito是否有效减少了抗生素的使用以及这些患者的就诊次数。18-49岁女性首次患急性膀胱炎,在就诊前90天内没有医疗保险使用史,在2018年4月至2021年3月期间,从JMDC索赔数据库中发现首次访视后30天内未住院.在他们第一次访问后的30天内,在有或没有Choreito的情况下,对首次服用抗菌药物处方的患者进行了以下方面的比较:(i)门诊就诊次数,(ii)抗菌药物处方总天数,以及(iii)根据年龄调整的抗菌药物处方数量,Charlson合并症指数,和COVID-19大流行期(2020年4月后)。对于有或没有Choreito处方的319和8515名患者,分别,多变量泊松回归分析显示,Choreito与患者总抗菌药物处方天数缩短5%显著相关(Beta,0.950;p=0.038),而门诊就诊次数和抗菌药物处方没有显著差异(分别为p=0.624和p=0.732).Choreito与抗菌药物联合使用的处方与女性急性膀胱炎的总抗菌药物使用量略有减少有关。
Choreito, a Japanese Kampo medicine, is used to treat Japanese female patients for the quick relief of inflammatory symptoms associated with acute cystitis. We evaluated whether
Choreito is effective in reducing antibiotic use and the number of clinic visits for these patients. Females aged 18-49 years who had acute cystitis for the first time, with no history of medical insurance use within 90 days prior to their visit, and no hospitalizations within the 30 days after their first visit were identified from the JMDC Claims Database between April 2018 and March 2021. For the 30 days after their first visit, patients who were given their first antimicrobial prescriptions with or without Choreito were compared regarding (i) the number of clinic visits, (ii) total antimicrobial prescription days, and (iii) the number of antimicrobial prescriptions adjusted for their age, Charlson comorbidity index, and the COVID-19 pandemic period (after April 2020). For the 319 and 8515 patients with or without a
Choreito prescription, respectively, multivariable Poisson regression analyses showed that
Choreito was significantly associated with a 5% shortening of a patient\'s total antimicrobial prescription days (Beta, 0.950; p = 0.038), whereas no significant difference was observed in the number of clinic visits and antimicrobial prescriptions (p = 0.624 and p = 0.732, respectively). The prescription of
Choreito in combination with antimicrobials was associated with a slight reduction in total antimicrobial use for acute cystitis among females.